Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.41 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.41 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3332812 | 0.99 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9AHPGDNPSR1 | |
| SCHEMBL3333930 | 0.96 | MAPK14 (0.49) | SMN1; SMN2NPC1RAB9AHPGDNPSR1 | |
| SCHEMBL3336523 | 0.87 | IP6K1 (0.47) | NPSR1LMNAROCK2ALDH1A1HDAC4 | |
| SCHEMBL3340784 | 0.86 | RAB9A (0.46) | SMN1; SMN2NPC1RAB9AHPGDMAPK14 | |
| SCHEMBL3337545 | 0.85 | RAB9A (0.47) | SMN1; SMN2NPC1RAB9AHPGDNPSR1 | |
| SCHEMBL3336495 | 0.84 | MKNK1 (0.42) | HPGDNPSR1LMNAMEN1KMT2A | |
| SCHEMBL3337490 | 0.84 | LMNA (0.44) | SMN1; SMN2NPC1RAB9AMAPK14LMNA | |
| SCHEMBL823721 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AHPGDNPSR1 | |
| SCHEMBL3336178 | 0.83 | LMNA (0.44) | SMN1; SMN2NPC1RAB9AMAPK14LMNA | |
| SCHEMBL3336047 | 0.83 | RXRA (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | claimed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | claimed |
| WO-2008009077-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | OPRD1, IFNAR1, NR4A1 | SMN1; SMN2 3749/4885NPC1 1545/4885RAB9A 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.